

02-10-2004

03 11:42 FAX 858 720 5125

002/020



102631751

10-15-2003

Form PTO-1594 (Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002) **RECORDATION FORM COVER SHEET TRADEMARKS ONLY** U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): Ambit Biosciences Corporation

Individual(s) Association
 General Partnership Limited Partnership
 Corporation-State Delaware
 Other:

Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies):
 Name: Forward Ventures IV, L.P.
 Internal Address:
 Street Address: 9393 Towne Centre Drive Suite 200
 City: San Diego
 State: CA Zip: 92121

Individual(s) citizenship:
 Association:
 General Partnership:
 Limited Partnership: Delaware
 Corporation-State:
 Other:

If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No
 (Designations must be a separate document from assignment)

Additional name(s) & address(es) attached? Yes No
 See Attachment A

3. Nature of Conveyance:
 Assignment Merge
 Security Agreement Change of Name
 Other:

Execution Date: October 14, 2003

4. Application Number(s) or Registration Number(s):
 A. Trademark Application No. (s):
See Schedule B
 Additional numbers attached? Yes No

B. Trademark Registration No. (s):
See Schedule B
 Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:
 Name: Bruce D. Grant MORRISON & FOERSTER LLP
 Internal Address: Atty. Dkt.: 558160000001
 Street Address: 3811 Valley Centre Drive, Suite 500
 City: San Diego State: CA Zip: 92130-2332

6. Total Number of applications and registrations involved: 7


7. Total fee (37 CFR 3.41) \$ 190.00

Enclosed
 Authorized to be charged to Deposit Account 190E
 Authorized to be charged to credit card
 (Form 2038 enclosed)

8. Deposit account number. 03-1952 88-185 referencing 558160000001
 (Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature:
 To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Bruce D. Grant  October 15, 2003
 Name of Person Signing Signature Date

Total number of pages including cover sheet, attachments, and document: 18 40E

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Assignment Services Division, facsimile no. (703) 300-6906, on the date shown below.
 Dated: 10/15/03 Signature: Judy Bridgewater (Judy Bridgewater)

CH \$190.00 031952 78199988

SD-167552

ATTACHMENT A TO RECORDATION FORM COVER SHEET

ADDITIONAL RECEIVING PARTIES

Forward Ventures I/B, L.P.
9393 Towne Centre Drive, Suite 200
San Diego, CA 92121
Limited Partnership: Delaware

Perseus-Soros Biopharmaceutical Fund, L.P.
888 Seventh Avenue, 29th Floor
New York, NY 10106
Limited Partnership: Delaware

GIMV NV
Karel Oomsstraat 37
2018 Antwerp, Belgium
Corporation: Belgium

Adviesbeheer GIMV Life Sciences NV
Karel Oomsstraat 37
2018 Antwerp, Belgium
Corporation: Belgium

Avalon Ventures VI, L.P.
4370 La Jolla Village Drive, Suite 685
San Diego, CA 92122
Limited Partnership: Delaware

Avalon GP Fund, L.P.
4370 La Jolla Village Drive, Suite 685
San Diego, CA 92122
Limited Partnership: Delaware

Tang Capital Partners, L.P.
4401 Eastgate Mall
San Diego, CA 92121
Limited Partnership: Unknown

sd-167588

**SCHEDULE B
TO RECORDATION FORM COVER SHEET**

	Serial Number	Reg. Number	Word Mark
1	78199988		AB ORION 1000
2	78199986		SPEEDGATE
3	76345630		AMBIT
4	76273761	2660663	AMBIT
5	76345922		AMBIT
6	75093728	2141422	AMBIT
7	75191817	2184820	BUILDGATES

7592

PATENT AND TRADEMARK SECURITY AGREEMENT

THIS PATENT AND TRADEMARK SECURITY AGREEMENT (this "Agreement"), dated as of October 14, 2003, is made between Ambit Biosciences Corporation, a Delaware corporation ("Grantor"), and the parties (each a "Secured Party" and, collectively, the "Secured Parties") named on the signature pages hereto.

Grantor and Secured Parties hereby agree as follows:

Section 1. Definitions: Interpretation.

(a) Terms Defined in Security Agreement. All capitalized terms used in this Agreement and not otherwise defined herein shall have the meanings assigned to them in the Security Agreement.

(b) Certain Defined Terms. As used in this Agreement, the following terms shall have the following meanings:

"Collateral" has the meaning set forth in Section 2.

"PTO" means the United States Patent and Trademark Office.

"Security Agreement" means the Security Agreement dated as of October 14, 2003 between Grantor and Secured Parties.

(c) Terms Defined in UCC. Where applicable and except as otherwise defined herein, terms used in this Agreement shall have the meanings assigned to them in the UCC.

(d) Interpretation. The rules of interpretation applicable to the Security Agreement shall also be applicable to this Agreement and are incorporated herein by this reference.

Section 2. Security Interest.

(a) Grant of Security Interest. As security for the payment and performance of the Obligations, including interest that accrues after the commencement by or against Grantor of any bankruptcy or insolvency proceeding naming such Person as the debtor in such proceeding, Grantor hereby assigns, transfers and conveys to Secured Parties, and grants a security interest in and mortgage to Secured Parties, all of Grantor's right, title and interest in, to and under the following property, in each case whether now or hereafter existing or arising or in which Grantor now has or hereafter owns, acquires or develops an interest and wherever located (collectively, the "Collateral"):

(i) all patents and patent applications, domestic or foreign, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses (including such patents and patent applications as described in Schedule A), all rights to sue for past, present or future infringement thereof, all rights arising therefrom and pertaining thereto and all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof;

(ii) all state (including common law), federal and foreign trademarks, service marks and trade names, and applications for registration of such trademarks, service marks and trade names, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses (including such marks, names and applications as described in Schedule B), whether registered or unregistered and wherever registered, all rights to sue for past, present or future infringement or unconsented use thereof, all rights arising therefrom and pertaining thereto and all reissues, extensions and renewals thereof;

(iii) the entire goodwill of or associated with the businesses now or hereafter conducted by Grantor connected with and symbolized by any of the aforementioned properties and assets;

(iv) all commercial tort claims associated with or arising out of any of the aforementioned properties and assets;

(v) all accounts, all intangible intellectual or other similar property and other general intangibles associated with or arising out of any of the aforementioned properties and assets and not otherwise described above, including all license payments and payments under insurance (whether or not any Secured Party or any Collateral Agent is the loss payee thereof) or any indemnity, warranty or guaranty payable by reason of loss or damage to or otherwise with respect to the foregoing Collateral; and

(vi) all products, proceeds and supporting obligations of or with respect to any and all of the foregoing Collateral.

(b) Continuing Security Interest. Grantor agrees that this Agreement shall create a continuing security interest in the Collateral which shall remain in effect until terminated in accordance with Section 12.

(c) Pari Passu Interests in the Collateral. Each Secured Party's interest in the Collateral shall be on a parity with the interests of all other Secured Parties, and the interest of each Secured Party in the Collateral shall be ratable in the proportion that the aggregate indebtedness then outstanding and unpaid under the Notes held by such Secured Party bears to the aggregate indebtedness then outstanding and unpaid under the Notes held by all Secured Parties.

Section 3. Supplement to Security Agreement. This Agreement has been granted in conjunction with the security interests granted to Secured Parties under the Security Agreement. The rights and remedies of Secured Parties and any Collateral Agent with respect to the security interests granted herein are without prejudice to, and are in addition to those set forth in the Security Agreement, all terms and provisions of which are incorporated herein by reference.

Section 4. Representations and Warranties. Grantor represents and warrants to Secured Parties that:

(a) Patents. A true and correct list of all of the existing Collateral consisting of U.S. patents and patent applications and/or registrations owned by Grantor, in whole or in part, is set forth in Schedule A.

(b) Trademarks. A true and correct list of all of the existing Collateral consisting of U.S. trademarks, trademark registrations and/or applications owned by Grantor, in whole or in part, is set forth in Schedule B.

Section 5. Further Acts. On a continuing basis, Grantor shall make, execute, acknowledge and deliver, and file and record in the proper filing and recording places, all such instruments and documents, and take all such action as may be necessary or advisable or may be requested by any Secured Party or any Collateral Agent to carry out the intent and purposes of this Agreement, or for assuring, confirming or protecting the grant or perfection of the security interest granted or purported to be granted hereby, to ensure Grantor's compliance with this Agreement or to enable any Secured Party or any Collateral Agent to exercise and enforce its rights and remedies hereunder with respect to the Collateral, including any documents for filing with the PTO and/or any applicable state office. Any Secured Party or any Collateral Agent may record this Agreement, an abstract thereof, or any other document describing Secured Parties' interest in the Collateral with the PTO, at the expense of Grantor.

Section 6. Authorization to Supplement. If Grantor shall obtain rights to any new trademarks, any new patentable inventions or become entitled to the benefit of any patent application or patent for any reissue, division, or continuation, of any patent, the provisions of this Agreement shall automatically apply thereto. Grantor shall give prompt notice in writing to each Secured Party and any Collateral Agent with respect to any such new trademarks or patents, or renewal or extension of any trademark registration. Without limiting Grantor's obligations under this Section 6, Grantor authorizes any Secured Party or any Collateral Agent to modify this Agreement by amending Schedules A or B to include any such new patent or trademark rights. Notwithstanding the foregoing, no failure to so modify this Agreement or amend Schedules A or B shall in any way affect, invalidate or detract from Secured Parties' continuing security interest in all Collateral, whether or not listed on Schedule A or B.

Section 7. Binding Effect. This Agreement shall be binding upon, inure to the benefit of and be enforceable by Grantor, Secured Parties and their respective successors and assigns and shall bind any Person who becomes bound as a debtor to this Agreement. Any Collateral Agent is expressly designated as a third party beneficiary hereof, and this Agreement shall also inure to the benefit of any Collateral Agent. Grantor may not assign, transfer, hypothecate or otherwise convey its rights, benefits, obligations or duties hereunder except as specifically permitted by the Security Agreement.

Section 8. Notices. All notices or other communications hereunder shall be in writing (including by facsimile transmission or by email) and mailed, sent or delivered to the respective parties hereto (in the case of Grantor) at or to its address, facsimile number or email address set forth below on the signature pages hereof or (in the case of the Secured Parties) at or to their respective addresses, facsimile numbers or email addresses set forth in the Security Agreement, or at or to such other address, facsimile number or email address as shall be designated by any party in a written notice to the other parties hereto. All such notices and other communications shall be deemed to be delivered when a record (within the meaning of the UCC) has been (i) delivered by hand; (ii) sent by mail upon the earlier of the date of receipt or five business days after deposit in the mail, first class (or air mail as to communications sent to or from the United States); (iii) sent by facsimile transmission; or (iv) sent by email.

396090 v2/SD

8hm\$02!.DOC

3.

Section 9. Governing Law. This Agreement shall be governed by, and construed in accordance with, the law of the State of California, except as required by mandatory provisions of law and to the extent the validity or perfection of the security interests hereunder, or the remedies hereunder, in respect of any Collateral are governed by the law of a jurisdiction other than California.

Section 10. Amendment; Conflict. Except as provided in Section 2.2 of the Purchase Agreement, no amendment to this Agreement, or any waiver of any provision hereof, shall be effective unless it is in writing and signed by the Majority Secured Parties and (in the case of any amendment) the Debtor; provided, however, that without the consent of all Secured Parties, no amendment, waiver or consent shall do any of the following: (i) change the definition of "Majority Secured Parties" or any definition or provision of this Agreement requiring the approval of the Secured Parties or some other specified amount of Secured Parties; or (ii) amend the provisions of this Section 10; and provided, further, that no amendment, waiver or consent shall, unless in writing and signed by the Collateral Agent, affect the rights, duties or obligations of the Collateral Agent under or in respect of this Agreement. To the extent that any provision of this Agreement conflicts with any provision of the Security Agreement, the provision giving Secured Parties greater rights or remedies shall govern, it being understood that the purpose of this Agreement is to add to, and not detract from, the rights granted to Secured Parties under the Security Agreement.

Section 11. Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts and by facsimile, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement.

Section 12. Termination. Upon payment and performance in full of all Obligations, the security interests created by this Agreement, and all representations, warranties and covenants of Debtor contained herein, shall terminate and Secured Parties shall promptly execute and deliver to Grantor such documents and instruments reasonably requested by Grantor as shall be necessary to evidence termination of all such security interests given by Grantor to Secured Parties hereunder, including cancellation of the security interests created by this Agreement by written notice from Secured Parties to the PTO.

[Signature pages to follow]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement,
as of the date first above written.

GRANTOR

Ambit Biosciences Corporation

By: _____

Title: CEO

Address:

9875 Towne Centre Drive
San Diego, CA 92117

Attn: Scott Salka


Fax: 858-334-2198

Email: ssalka@ambitbio.com

396090 v2/SD
8hr\$021.DOC

**SECURED PARTIES:
FORWARD VENTURES IV, L.P.**

By: Forward IV Associates, LLC
Its: General Partner


By: 
Standish M. Fleming,
Managing Member

Address:
9393 Towne Centre Drive, Suite 200
San Diego, CA 92121

Telephone: (858) 677-6077
Facsimile: (858) 452-8799

FORWARD VENTURES IV B, L.P.

By: Forward IV Associates, LLC
Its: General Partner

By: 
Standish M. Fleming,
Managing Member

Address:
9393 Towne Centre Drive, Suite 200
San Diego, CA 92121

Telephone: (858) 677-6077
Facsimile: (858) 452-8799

REGISTRATION
STATE OF CALIFORNIA
SD-396090-v2-Parent and Trademark Security Agreement


PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP

By: Perseus-Soros Partners, LLC, Its General Partner

By: SFM Participation, L.P., Its Managing Member

By: SFM AH, LLC, Its General Partner

By: Soros Private Funds Management LLC, Its Managing Member

By: 
JOHN F. BROWN
Attorney-in-Fact
Title: Attorney-in-Fact

Address: Perseus-Soros Biopharmaceutical Fund, L.P.
888 Seventh Avenue, 29th Floor
New York, NY 10106
Attention: Steve Elms

with a copy to:


Perseus-Soros Biopharmaceutical Fund, L.P.
C/O Soros Fund Management LLC
888 Seventh Avenue, 31st Floor
New York, NY 10106
Attention: Richard D. Holahan, Jr., Esq.


and

Paul, Weiss, Rifkind, Wharton & Garrison LLP
1285 Avenue of the Americas
New York, New York 10019-6064
Attention: Bruce A. Gutenplan, Esq.


396090 v2/SD
8hm5021.DOC


GIMV NV


By: Marc Verwiltse
Its: CFO


Dirk Boogmans
President & CEO

ADVIESBEHEER GIMV LIFE SCIENCES NV



By: Marc Verwiltse
Its: Director


Dirk Boogmans
Director

396090 v2/SD
8hms\$021.DOC

AVALON VENTURES VI, L.P.

By Avalon Ventures GP, LLC, its General Partner




By: Kevin J. Kinsella

Its: Managing Member

AVALON GP FUND, LLC

By Avalon Ventures GP, LLC, its Manager




By: Kevin J. Kinsella

Its: Managing

396090 v2/SD
81m5021.DOC

TANG CAPITAL PARTNERS, L.P.



By: Kevin C. Tang
Managing Director
Tang Capital Management, LLC
General Partner of
Tang Capital Partners, LP

396090 v2/SD
8lm3021.DOC

SCHEDULE A
to the Patent and Trademark Security Agreement

Patents and Patent Applications.

The Company has filed the following patent applications with the United States Patent and Trademark Office and with foreign patent offices:

STATUS REPORT FOR
AMBIT BIOSCIENCES CORPORATION

Client Number: 49662

Prepared on: 7/25/2003

ATTY REF # CLJ REF #	CTY	TITLE	APP # FILE DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S) (FIRST SD)	OWNER
49662- 20001.00	US	METHOD TO IDENTIFY GENES USING SMALL MOLECULE PROBE (*reverse screen*)	09/653,668 9/1/2000	60/152,471 9/3/1999	National	AUSTIN, D. MCKENZIE, KATHLEEN SAVINOV, SERGEY SCHE, PAUL	YALE
49662- 20001.40	WO	METHOD TO IDENTIFY GENES USING SMALL MOLECULE PROBE	PCT/US00/24124 9/1/2000	09/653,668 9/1/2000	Patent Coo	AUSTIN, D.	YALE
49662- 20001.41	AU	METHOD TO IDENTIFY GENES USING SMALL MOLECULE PROBE	7343700 9/1/2000	PCT/US00/241 24 9/1/2000	Patent Coo	AUSTIN, D.	YALE
49662- 20001.42	CA	METHOD TO IDENTIFY GENES USING SMALL MOLECULE PROBE	2383188 9/1/2000	PCT/US00/241 24 9/1/2000	Patent Coo	AUSTIN, D.	YALE
49662- 20001.43	EP	METHOD TO IDENTIFY GENES USING SMALL MOLECULE PROBE	009614926 9/1/2000	PCT/US00/241 24 9/1/2000	PCT/EPC Ap	AUSTIN, D.	YALE
49662- 20001.44	JP	METHOD TO IDENTIFY GENES USING SMALL MOLECULE PROBE	2001521769 9/1/2000	PCT/US00/241 24 9/1/2000	Patent Coo	AUSTIN, D.	YALE
49662- 20001.45	HK	METHOD TO IDENTIFY GENE FUNCTION USING SMALL MOLECULE PROBE	PENDING 12/9/2002	009614926 9/1/2000	European P	AUSTIN, D.	YALE
49662- 20003.00	US	PHAGE DISPLAY AFFINITY FILTER AND FORWARD SCREEN (*forward screen*)	10/116,442 4/2/2002		National	TREIBER, DANIEL K. LOCKHART, DAVID J. ZARRINKAR, PATRICK, P.	AMBIT

396096 v2/SD

8hm\$021.DOC

ATTY REF# CU REF#	CTY	TITLE	APP # FILE DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S) (FIRST SIX)	OWNER
49662- 20003.20	US	PHAGE DISPLAY AFFINITY AND SPECIFICITY FILTERS AND FORWARD SCREEN "CIP"	10/406,797 4/2/2003	10/115,442 4/2/2002	National	TREIBER, DANIEL K. LOCKHART, DAVID J. ZARRINKAR, PATRICK P.	AMBIT
49662- 20003.40	WO	PHAGE DISPLAY AFFINITY AND SPECIFICITY FILTERS AND FORWARD SCREEN	PCT/US03/10247 4/2/2003	10/115,442 4/2/2002	Patent Coo	TREIBER, D.	AMBIT
49662- 20005.00	US	UNCOUPLING OF DNA INSERT PROPAGATION AND EXPRESSION OF PROTEIN FOR PHAGE DISPLAY	10/214,654 8/7/2002		National	CICERI, PIETRO ZARRINKAR, PATRICK P. LOCKHART, DAVID J. TREIBER, DANIEL K.	AMBIT
49662- 20005.40	WO	UNCOUPLING OF DNA INSERT PROPAGATION AND EXPRESSION OF PROTEIN FOR PHAGE DISPLAY	PCT/US03/24221 8/1/2003	10/214,654 8/7/2002	Patent Coo	CICERI, PIETRO ZARRINKAR, PATRICK P. LOCKHART, DAVID J. TREIBER, DANIEL K.	AMBIT
49662- 20007.00	US	PROTEIN FAMILY PROFILING TOOL AND METHODS	To be filed based on the provisional	6/20/2003	National	ZARRINKAR, PATRICK	AMBIT
49662- 20007.40	WO	PROTEIN FAMILY PROFILING TOOL AND METHODS	To be filed based on the provisional	6/20/2003	Patent Coo	ZARRINKAR, PATRICK	AMBIT
49662- 20009.00	US	TARGETS FOR ATORVASTATIN ACTION AND ASSAYS THEREOF	To be filed based on the provisional	6/20/2003	National	ZARRINKAR, PATRICK P.	AMBIT
49662- 20009.40	WO	TARGETS FOR ATORVASTATIN ACTION AND ASSAYS THEREOF	To be filed based on the provisional	6/20/2003	Patent Coo	ZARRINKAR, PATRICK P.	AMBIT
49662- 20012.00	US	TARGETS FOR KINASE INHIBITORS ACTION AND ASSAYS THEREOF	To be filed based on the provisional	7/17/2003	National	ZARRINKAR, PATRICK P.	AMBIT
49662- 20012.40	WO	TARGETS FOR KINASE INHIBITORS ACTION AND ASSAYS THEREOF	To be filed based on the provisional	7/17/2003	Patent Coo	ZARRINKAR, PATRICK P.	AMBIT
49662- 20013.00	US	USING RALOXIFENE TO TREAT DISEASE	To be filed based on the provisional		National	ZARRINKAR, PATRICK P.	AMBIT
49662- 20013.40	WO	USING RALOXIFENE TO TREAT DISEASE	To be filed based on the provisional		Patent Coo	ZARRINKAR, PATRICK P.	AMBIT
49662- 20014.00	US	STATIN DERIVATIVES AND THE TREATMENT OF DISEASE	To be filed based on the provisional	5/16/2003	National	MEHTA, SHAMAL ANIL MILANOV, ZDRAVKO VASSILEV PATEL, HITESH LOCKHART, DAVID	AMBIT
49662- 20014.40	WO	STATIN DERIVATIVES AND THE TREATMENT OF DISEASE	To be filed based on the provisional	5/16/2003	Patent Coo	MEHTA, SHAMAL ANIL MILANOV, ZDRAVKO VASSILEV PATEL, HITESH LOCKHART, DAVID	AMBIT
49662- 30007.00	US	PROTEIN FAMILY PROFILING TOOL AND METHODS	60/480,587 6/20/2003		National	ZARRINKAR, PATRICK	AMBIT

396090 v2/SD

8hm\$021.DOC

ATTY REF# CLI REF#	CTY	TITLE	APP # FILE DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S) (FIRST SIX)	OWNER
49662- 30009.00	US	TARGETS FOR ATORVASTATIN ACTION AND ASSAYS THEREOF	60/480,475 6/20/2003		National	ZARRINKAR, PATRICK P.	AMBIT
49662- 30009.01	US	IDENTIFYING COMPOUNDS THAT CAUSE UNWANTED EFFECTS	60/480,289 6/20/2003		National	ZARRINKAR, PATRICK P.	AMBIT
49662- 30009.02	US	TARGETS FOR ATORVASTATIN ACTION AND ASSAYS THEREOF	60/488,178 7/16/2003		National	LOCKHART, DAVID J. TREIBER, DANIEL K. ZARRINKAR, PATRICK P. FABIAN, MILES A. PATEL, HITESH K.	AMBIT
49662- 30009.03	US	IDENTIFYING COMPOUNDS THAT CAUSE UNWANTED EFFECTS	60/488,172 7/16/2003		National	LOCKHART, DAVID J. TREIBER, DANIEL K. ZARRINKAR, PATRICK P. FABIAN, MILES A. PATEL, HITESH K.	AMBIT
49662- 30011.00	US	TARGETS FOR GEFITINIB AND FASUDIL ACTION AND ASSAYS THEREOF	In drafting; to be filed		National	ZARRINKAR, PATRICK P.	AMBIT
49662- 30012.00	US	TARGETS FOR KINASE INHIBITORS ACTION AND ASSAYS THEREOF	60/488,513 7/17/2003		National	ZARRINKAR, PATRICK P.	AMBIT
49662- 30014.00	US	STATIN DERIVATIVES AND THE TREATMENT OF DISEASE	60/471,425 5/16/2003		National	MENTA, SHAMAL ANIL MILANOV, ZDRAVKO VASSILEV PATEL, HITESH LOCKHART, DAVID	AMBIT
		Now applications for AB series proprietary compounds in process					

396090 v2/SD

8hm\$021.DOC

SCHEDULE B
to the Patent and Trademark Security Agreement

U.S. Registered Trademarks of Grantor

	Serial Number	Reg. Number	Word Mark	Check Status	Live/Dead
1	78199988		AB ORION 1000	TARR	LIVE
2	78199986		SPEEDGATE	TARR	LIVE
3	76345630		AMBIT	TARR	LIVE
4	76273761	2660663	AMBIT	TARR	LIVE
5	76345922		AMBIT	TARR	LIVE
6	75093728	2141422	AMBIT	TARR	LIVE
7	75191817	2184820	BUILDGATES	TARR	LIVE

396090 v1/CD
8hm\$021.DOC